Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MIST

MIST - Milestone Pharmaceuticals Inc Stock Price, Fair Value and News

$1.95-0.06 (-2.99%)
Market Closed

12/100

MIST

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

12/100

MIST

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.58

Target 3M

$1.78

Target 6M

$1.68

MIST Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MIST Price Action

Last 7 days

-3.0%

Last 30 days

-4.4%

Last 90 days

3.7%

Trailing 12 Months

-1.5%

MIST RSI Chart

MIST Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MIST Valuation

Market Cap

166.1M

Price/Earnings (Trailing)

-2.86

Price/Sales (Trailing)

163.53

EV/EBITDA

-3.58

Price/Free Cashflow

-3.85

MIST Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.58

Target 3M

$1.78

Target 6M

$1.68

MIST Fundamentals

MIST Revenue

Revenue (TTM)

1.0M

MIST Earnings

Earnings (TTM)

-58.0M

Earnings Growth (Yr)

-26.31%

Earnings Growth (Qtr)

8.05%

MIST Profitability

EBT Margin

-5177.10%

Return on Equity

-282.97%

Return on Assets

-66.11%

Free Cashflow Yield

-25.98%

MIST Investor Care

Shares Dilution (1Y)

59.71%

Diluted EPS (TTM)

-0.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240000
20235.5M6.0M4.5M1.0M
202211.7M08.3M5.0M
20214.3M7.9M11.4M15.0M
20202.5M2.0M1.2M726.0K
20191.2M1.7M2.1M2.6M
2018000711.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Milestone Pharmaceuticals Inc

MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
 CEO
 WEBSITEmilestonepharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES39

Milestone Pharmaceuticals Inc Frequently Asked Questions

MIST is the stock ticker symbol of Milestone Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Milestone Pharmaceuticals Inc is 166.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MIST's fair value in chart for subscribers.

The fair value guage provides a quick view whether MIST is over valued or under valued. Whether Milestone Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Milestone Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MIST.

As of Wed Jan 28 2026, MIST's PE ratio (Price to Earnings) is -2.86 and Price to Sales (PS) ratio is 163.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MIST PE ratio will change depending on the future growth rate expectations of investors.